QPROTEOME
LIVE

Serial Number

78629724

Owner

QIAGEN GMBH

Attorney

Victoria Friedman

Filing Date

May 13, 2005

Add to watchlist:

No watchlists yet
View on USPTO

QPROTEOME Trademark

Serial Number: 78629724 • Registration: 3960628

QPROTEOME is a trademark filed by QIAGEN GMBH on May 13, 2005. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics). The application is currently registered and active.

Owner Contact Info

QIAGEN GMBH (212 trademarks)

HILDEN D-4010 , DE

Entity Type: 03

Trademark Details

Filing Date

May 13, 2005

Registration Date

May 17, 2011

Published for Opposition

March 1, 2011

Goods & Services

[ Scientific apparatus, instruments and equipment, namely, binding supports, crystallization supports, columns, tube extenders, collection tubes, and cartridge filters; optical apparatuses and instruments for use in protein processing; calculating machines; electrical and electronic apparatuses and instruments for research and examination purposes for use in protein processing; laboratory equipment, measuring apparatus and instruments for medical or veterinary medical diagnostic purposes, for the separation, purification, and/or isolation of biopolymers, macromolecules and biological active substances and proteins from biological material, namely, soluble protein separation kits containing buffers and reagents for the preparation of separate protein fractions from cleared cell lysates; related computer software for analysis of glycan makeup and glycoproteins ]

[ Diagnostic preparations and products for use in human medicine and veterinary medicine, namely, solutions for protein processing, protease inhibitor solutions, detergent solutions, buffers, reagents, resins, enzymes, proteins, and solvents for the separation, isolation and purification of biopolymers, in particular of proteins, macromolecules and biologically active substances; chemical, biochemical products, namely, solutions for protein processing, protease inhibitor solutions, detergent solutions, buffers, reagents, resins, enzymes, proteins, and solvents, in particular for performing separation, isolation and/or purification methods for biopolymers, in particular proteins, macromolecules and biologically active substances for medical diagnostic purposes; kits comprising products for medical or veterinary medical diagnostic purposes, namely, solutions for protein processing, protease inhibitor solutions, detergent solutions, buffers, reagents, resins, enzymes, proteins, and solvents, in particular for separation, isolation and/or purification of biopolymers, in particular of proteins, macromolecules and biological active substances, in particular of proteins from biological material; cell compartment kits containing extraction buffers and reagents for medical use; nuclear protein kits containing buffers for isolation and fractionation of nucleic acid binding proteins for medical use; nuclear subfractionation kits containing buffers for isolation and fractionation of nucleic acid binding proteins for medical use; total glycoprotein kits containing buffers and reagents for medical use; mannose glycoprotein kits containing buffers and reagents for medical use; sialic glycoprotein kits containing buffers and reagents for medical use; o-glycan glycoprotein kits containing buffers and reagents for medical use; mitochondria isolation kits containing buffers and reagents for isolation of high-purity mitochondria preparations for medical use; plasma membrane protein kits containing buffers and reagents for isolation of plasmamembrane proteins for medical use; glycoarray kits containing buffers and reagents for medical use; albumin/IgG depletion kits containing buffers and reagents for medical use; murine albumin depletion kits containing buffers and reagents for medical use; bacterial protein prep kits containing buffers and reagents for medical use; mammalian protein prep kits containing buffers and reagents for medical use; collection tubes and columns for analysis of glycan makeup and glycoproteins for medical use ]

Chemical, biochemical and biotechnical products for industrial and scientific purposes, namely, solutions for protein processing, protease inhibitor solutions, detergent solutions, buffers, reagents, [ resins, enzymes, proteins, ] and solvents for scientific, research, or industrial use; [ biotechnological products, namely, solutions for protein processing, protease inhibitor solutions, detergent solutions, buffers, reagents, resins, enzymes, proteins, and solvents, in particular for performing separation, isolation and/or purification methods for biopolymers, in particular proteins, macromolecules and biologically active substances for diagnostic purposes; diagnostic preparations, except for use in human medicine and veterinary medicine; chemical reagents and solvents except those for purposes in human medicine and veterinary medicine to perform separation, isolation, and/or purification methods for biopolymers, in particular for proteins, macromolecules and biologically active substances; ] kits comprising chemical products, namely, solutions for protein processing, protease inhibitors solutions, detergent solutions, buffers, reagents,[ resins, enzymes, proteins, ] and solvents, for the separation and isolation and/or purification of biopolymers, in particular proteins, macromolecules and biologically active substances, in particular proteins from biological material; [ cell compartment kits containing extraction buffers and reagents for scientific use; nuclear protein kits containing buffers for isolation and fractionation of nucleic acid binding proteins for scientific use; nuclear subfractionation kits containing buffers for isolation and fractionation of nucleic acid binding proteins for scientific use; total glycoprotein kits containing buffers and reagents for scientific use; mannose glycoprotein kits containing buffers and reagents for scientific use; sialic glycoprotein kits containing buffers and reagents for scientific use; o-glycan glycoprotein kits containing buffers and reagents for scientific use; ] mitochondria isolation kits containing buffers and reagents for isolation of high-purity mitochondria preparations for scientific use [ ; plasma membrane protein kits containing buffers and reagents for isolation of plasmamembrane proteins for scientific use; glycoarray kits containing buffers and reagents for scientific use; albumin/IgG depletion kits containing buffers and reagents for scientific use; murine albumin depletion kits containing buffers and reagents for scientific use; bacterial protein prep kits containing buffers and reagents for scientific use; mammalian protein prep kits containing buffers and reagents for scientific use; collection tubes and columns for analysis of glycan makeup and glycoproteins for scientific use ]

Filing History

NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Aug 11, 2021 NA89
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Aug 11, 2021 RNL1
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Aug 11, 2021 89AG
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Aug 10, 2021 APRE
TEAS SECTION 8 & 9 RECEIVED
Apr 22, 2021 E89R
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
May 17, 2020 REM2
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Jun 10, 2017 NA85
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Jun 10, 2017 C15P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jun 9, 2017 APRE
TEAS SECTION 8 & 15 RECEIVED
Apr 20, 2017 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
May 17, 2016 REM1
REGISTERED-PRINCIPAL REGISTER
May 17, 2011 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 1, 2011 NPUB
PUBLISHED FOR OPPOSITION
Mar 1, 2011 PUBO
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jan 21, 2011 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 14, 2011 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 14, 2011 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 14, 2011 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 14, 2011 TROA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Nov 3, 2010 CHAN
ASSIGNED TO LIE
Nov 3, 2010 ALIE
PAPER RECEIVED
Oct 18, 2010 MAIL
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 1, 2010 GNRN
NON-FINAL ACTION E-MAILED
Oct 1, 2010 GNRT
NON-FINAL ACTION WRITTEN
Oct 1, 2010 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 8, 2010 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 8, 2010 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 8, 2010 TROA
NOTIFICATION OF PRIORITY ACTION E-MAILED
Jul 28, 2010 GPRN
PRIORITY ACTION E-MAILED
Jul 28, 2010 GPRA
PRIORITY ACTION WRITTEN
Jul 28, 2010 CPRA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 8, 2010 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 8, 2010 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 8, 2010 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 7, 2010 GNRN
NON-FINAL ACTION E-MAILED
Jun 7, 2010 GNRT
NON-FINAL ACTION WRITTEN
Jun 7, 2010 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
May 13, 2010 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 13, 2010 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 13, 2010 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 5, 2009 GNRN
NON-FINAL ACTION E-MAILED
Dec 5, 2009 GNRT
NON-FINAL ACTION WRITTEN
Dec 5, 2009 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 4, 2009 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 4, 2009 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 4, 2009 TROA
UNDELIVERABLE MAIL - COURTESY COPY MAILED
Jun 26, 2009 UNDC
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 25, 2009 GNRN
NON-FINAL ACTION E-MAILED
Jun 25, 2009 GNRT
NON-FINAL ACTION WRITTEN
Jun 25, 2009 CNRT
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Jun 1, 2009 ZZZX
WITHDRAWN FROM PUB - OG REVIEW QUERY
May 31, 2009 PBCR
LAW OFFICE PUBLICATION REVIEW COMPLETED
May 18, 2009 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
May 18, 2009 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 1, 2009 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 30, 2009 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 30, 2009 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 12, 2009 GNRN
NON-FINAL ACTION E-MAILED
Jan 12, 2009 GNRT
NON-FINAL ACTION WRITTEN
Jan 12, 2009 CNRT
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Nov 28, 2008 ZZZX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Nov 21, 2008 PBCR
LAW OFFICE PUBLICATION REVIEW COMPLETED
Nov 12, 2008 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 11, 2008 CNSA
AMENDMENT FROM APPLICANT ENTERED
Oct 16, 2008 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 16, 2008 CRFA
PAPER RECEIVED
Oct 9, 2008 MAIL
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 8, 2008 GNRN
NON-FINAL ACTION E-MAILED
Apr 8, 2008 GNRT
NON-FINAL ACTION WRITTEN
Apr 8, 2008 CNRT
AMENDMENT FROM APPLICANT ENTERED
Jan 15, 2008 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 15, 2008 CRFA
PAPER RECEIVED
Jan 7, 2008 MAIL
UNDELIVERABLE MAIL - COURTESY COPY MAILED
Jul 2, 2007 UNDC
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 2, 2007 GNRN
NON-FINAL ACTION E-MAILED
Jul 2, 2007 GNRT
NON-FINAL ACTION WRITTEN
Jul 2, 2007 CNRT
ASSIGNED TO EXAMINER
Jun 12, 2007 DOCK
AMENDMENT FROM APPLICANT ENTERED
Apr 23, 2007 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 23, 2007 CRFA
PAPER RECEIVED
Apr 20, 2007 MAIL
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Mar 29, 2007 RCSC
ASSIGNED TO LIE
Mar 29, 2007 ALIE
LETTER OF SUSPENSION E-MAILED
Sep 10, 2006 GNSL
SUSPENSION LETTER WRITTEN
Sep 10, 2006 CNSL
AMENDMENT FROM APPLICANT ENTERED
Jun 29, 2006 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 19, 2006 CRFA
PAPER RECEIVED
Jun 19, 2006 MAIL
NON-FINAL ACTION E-MAILED
Dec 19, 2005 GNRT
NON-FINAL ACTION WRITTEN
Dec 19, 2005 CNRT
ASSIGNED TO EXAMINER
Dec 9, 2005 DOCK
NEW APPLICATION ENTERED
May 20, 2005 NWAP